Phase I trial to assess safety and pharmacokinetics of Gefitinib plus S-1 combination therapy in patients with advanced adenocarcinoma lung

Phase I trial to assess safety and pharmacokinetics of Gefitinib plus S-1 combination therapy in patients with advanced adenocarcinoma lung - Phase I trial of Gefitinib plus S-1 combination therapy for advanced adenocarcinoma of the lung

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001594

Enrollment

Registered

2008-12-22

Start date

2008-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: a

Exclusion criteria

Exclusion criteria: a

Design outcomes

Primary

Measure	Time frame
Recommended dose of Gefitinib and S-1 combination therapy	—

Countries

Japan

Outcome results